Picture of virus

Open Access research that helps to deliver "better medicines"...

Strathprints makes available scholarly Open Access content by the Strathclyde Institute of Pharmacy and Biomedical Sciences (SIPBS), a major research centre in Scotland and amongst the UK's top schools of pharmacy.

Research at SIPBS includes the "New medicines", "Better medicines" and "Better use of medicines" research groups. Together their research explores multidisciplinary approaches to improve understanding of fundamental bioscience and identify novel therapeutic targets with the aim of developing therapeutic interventions, investigation of the development and manufacture of drug substances and products, and harnessing Scotland's rich health informatics datasets to inform stratified medicine approaches and investigate the impact of public health interventions.

Explore Open Access research by SIPBS. Or explore all of Strathclyde's Open Access research...

Risk factors for resistance and multidrug resistance in community urine isolates : population level analysis using the NHS Scotland Infection Intelligence Platform

Malcolm, William and Fletcher, Eilidh and Kavanagh, Kimberley and Deshpande, Ashutosh and Wiuff, Camilla and Marwick, Charis and Bennie, Marion (2017) Risk factors for resistance and multidrug resistance in community urine isolates : population level analysis using the NHS Scotland Infection Intelligence Platform. Journal of Antimicrobial Chemotherapy. ISSN 0305-7453 (In Press)

[img] Text (Malcolm-etal-JAC2017-Risk-factors-for-resistance-and-multidrug-resistance-in-community-urine)
Malcolm_etal_JAC2017_Risk_factors_for_resistance_and_multidrug_resistance_in_community_urine.pdf
Accepted Author Manuscript
Restricted to Repository staff only until 3 September 2018.

Download (1MB) | Request a copy from the Strathclyde author

Abstract

Background: Urinary tract infections (UTI) are common. Antibiotic treatment is usually empirical, with the risk of under-treatment of resistant infections. Objectives: To characterise risk factors for antibiotic resistant community urine isolates using routine record linked health data. Methods: Within the National Health Service Scotland Infection Intelligence Platform, national surveillance patient-level data on community urine isolates (January 2012-June 2015) were linked to hospital activity and community prescribing data. Associations between age, gender, comorbidity, care home residence, previous hospitalisations, antibiotic exposure, and resistant (any antibiotic) or MDR (≥1 antibiotic from ≥3 categories) urinary isolates were quantified using multivariable logistic regression. Results: Of 40,984 isolates, 28% were susceptible, 45% resistant, and 27% MDR. Exposure to ≥ 4 different antibiotics in the prior six months increased MDR risk, OR 6.81 (95%CI 5.73-8.11). MDR was associated with ≥29 DDD cumulative exposure, in the prior six months, for any antibiotic (OR 6.54, 95%CI 5.88-7.27), nitrofurantoin (OR 8.56, 95%CI 6.56-11.18) and trimethoprim (OR 14.61, 95%CI10.53-20.27). Associations persisted for 10-12 months for nitrofurantoin (OR 2.31, 95%CI 1.93-2.76) and trimethoprim (OR 1.81, 95%CI 1.57-2.09). Increasing age, comorbidity, previous hospitalisation and care home residence were independently associated with MDR. For resistant isolates the factors were the same but with weaker associations. Conclusion: We have demonstrated, using national capability at scale, the risk of MDR in community urine isolates for the first time and quantified the cumulative and sustained impact of antibiotic exposure. These data will inform the development of decision support tools for UTI treatment.